Abstract
Several lines of evidence suggest that the dopaminergic nervous system contributes to methamphetamine (METH) dependence, and there is increasing evidence of antagonistic interactions between dopamine and adenosine receptors in METH abusers. We therefore hypothesized that variations in the A1 adenosine receptor (ADORA1) gene modify genetic susceptibility to METH dependence/psychosis. In this study, we identified 7 single nucleotide polymorphisms (SNPs) in exons and exon-intron boundaries of the ADORA1 gene in a Japanese population. A total of 171 patients and 229 controls were used for an association analysis between these SNPs and METH dependence/psychosis. No significant differences were observed in either the genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. In the clinical feature analyses, no significant associations were observed among latency of psychosis, prognosis of psychosis, and spontaneous relapse. These results suggest that the ADORA1 gene variants may make little or no contribution to vulnerability to METH dependence/psychosis.
Keywords: Single nucleotide polymorphism, SNP, variation, human, Japanese, MAP, abuse, dopamine, adenosinergic function, dopaminergic system
Current Neuropharmacology
Title: Association Analysis of the Adenosine A1 Receptor Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis
Volume: 9 Issue: 1
Author(s): > Kobayashi, Hiroshi Ujike, Nakao Iwata, Toshiya Inada, Mitsuhiko Yamada, Yoshimoto Sekine, Naohisa Uchimura, Masaomi Iyo, Norio Ozaki, Masanari Itokawa and Ichiro Sora
Affiliation:
Keywords: Single nucleotide polymorphism, SNP, variation, human, Japanese, MAP, abuse, dopamine, adenosinergic function, dopaminergic system
Abstract: Several lines of evidence suggest that the dopaminergic nervous system contributes to methamphetamine (METH) dependence, and there is increasing evidence of antagonistic interactions between dopamine and adenosine receptors in METH abusers. We therefore hypothesized that variations in the A1 adenosine receptor (ADORA1) gene modify genetic susceptibility to METH dependence/psychosis. In this study, we identified 7 single nucleotide polymorphisms (SNPs) in exons and exon-intron boundaries of the ADORA1 gene in a Japanese population. A total of 171 patients and 229 controls were used for an association analysis between these SNPs and METH dependence/psychosis. No significant differences were observed in either the genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. In the clinical feature analyses, no significant associations were observed among latency of psychosis, prognosis of psychosis, and spontaneous relapse. These results suggest that the ADORA1 gene variants may make little or no contribution to vulnerability to METH dependence/psychosis.
Export Options
About this article
Cite this article as:
Kobayashi >, Ujike Hiroshi, Iwata Nakao, Inada Toshiya, Yamada Mitsuhiko, Sekine Yoshimoto, Uchimura Naohisa, Iyo Masaomi, Ozaki Norio, Itokawa Masanari and Sora Ichiro, Association Analysis of the Adenosine A1 Receptor Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795016958
DOI https://dx.doi.org/10.2174/157015911795016958 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and its Neuroprotective Effects in Mice After Intracranial Hemorrhage
CNS & Neurological Disorders - Drug Targets The Neuronal Cytoskeleton as a Potential Therapeutical Target in Neurodegenerative Diseases and Schizophrenia
Current Drug Targets - CNS & Neurological Disorders Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology Physiology and Pharmacology of the Vanilloid Receptor
Current Neuropharmacology Cannabinoids and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Small Neuroscience: The Nanostructure of the Central Nervous System and Emerging Nanotechnology Applications
Current Nanoscience The Evolution of Pharmacological Treatment for Parkinsons Disease
Recent Patents on CNS Drug Discovery (Discontinued) Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Role of Infrared Spectroscopy and Imaging in Cancer Diagnosis
Current Medicinal Chemistry The Role of Oxidative Stress in Huntington’s Disease: Are Antioxidants Good Therapeutic Candidates?
Current Drug Targets Neurotrophic Factors for Retinal Ganglion Cell Neuropathy - With a Special Reference to Diabetic Neuropathy in the Retina
Current Diabetes Reviews Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
CNS & Neurological Disorders - Drug Targets Endogeneous Remyelination: Findings in Human Studies
CNS & Neurological Disorders - Drug Targets β -Amyloid: A Disease Target or a Synaptic Regulator Affecting Age-Related Neurotransmitter Changes?
Current Pharmaceutical Design Voltage Gated Calcium Channels as Targets for Analgesics
Current Topics in Medicinal Chemistry Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Natural Compounds Therapeutic Features in Brain Disorders by Experimental, Bioinformatics and Cheminformatics Methods
Current Medicinal Chemistry Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease
Recent Patents on CNS Drug Discovery (Discontinued) Novel Medication Targets for the Treatment of Alcoholism: Preclinical Studies
Recent Patents on CNS Drug Discovery (Discontinued) Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Current Pharmaceutical Design